The Tuberculosis Drug Accelerator at Year 10: What Have We Learned?
Landmark Review Published in Nature Medicine
LGENIA's Chief Executive Officer and Chief Scientific Officer, Dr. Philip Hipskind, recently multi-authored the paper "The Tuberculosis Drug Accelerator at year 10: what have we learned?" in the journal Nature Medicine.
Published in Nature Medicine: "The tuberculosis drug accelerator at year 10: what have we learned?"
A comprehensive analysis of one of the most successful public-private partnerships in global health research.
The Tuberculosis Drug Accelerator, an experiment designed to facilitate collaboration in tuberculosis drug discovery by breaking down barriers among competing labs and institutions, has reached a 10-year landmark.
The paper reviews the consortium's achievements, advantages, and limitations and advocates for the application of similar models to other diseases.
Breaking Down Barriers in Drug Discovery
Launched in 2011 by the Bill and Melinda Gates Foundation, the TB Drug Accelerator brought together leading pharmaceutical companies, academic institutions, and biotechnology firms in an unprecedented collaborative effort to accelerate the discovery of new tuberculosis treatments.
"The TB Drug Accelerator has demonstrated that when we work together—sharing risks, resources, and knowledge—we can achieve far more than any single organization could accomplish alone. This model of open collaboration has become a blueprint for addressing other global health challenges."
Key Achievements and Insights
The consortium's unique approach—combining competitive collaboration with open science principles—has fundamentally changed the landscape of TB drug discovery. Key achievements include:
- Collaborative framework: 20+ member organizations representing diverse expertise from pharma, biotech, and academia
- Novel target identification: Discovery of new biological pathways for TB drug development
- Advanced screening capabilities: Development of high-throughput screening assays
- Clinical progress: Multiple drug candidates progressed to clinical trials
- Open innovation model: Shared data and resources accelerating discovery timelines
- Global capacity building: Training programs and technology transfer to endemic countries
Looking Forward: Lessons for Other Diseases
The review not only celebrates the progress made but also provides a roadmap for applying similar collaborative models to other challenging diseases. The TB Drug Accelerator's success in breaking down traditional barriers between competing organizations offers valuable lessons for the broader pharmaceutical industry.
By pooling resources and sharing pre-competitive research, member organizations have been able to explore more diverse approaches and reduce duplicated efforts, ultimately accelerating the path from discovery to clinical application.
About the TB Drug Accelerator: Launched in 2011 by the Bill and Melinda Gates Foundation, the TB Drug Accelerator is a public-private partnership dedicated to accelerating the discovery and development of new tuberculosis treatments through collaborative research and open innovation.
About LGENIA: LGENIA is a biotechnology company focused on discovering new medications for debilitating diseases, with particular expertise in tuberculosis, malaria, and Alzheimer's disease research.
Read the full Nature Medicine article: The tuberculosis drug accelerator at year 10: what have we learned?